British pharmaceutical manufacturer GlaxoSmithKline has been fined £297m in relation to allegations of bribery in China.
A statement released by GSK said that, according to Chinese law, the company had “offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government personnel.” The guilty verdict, handed down in Changsha Intermediate People’s Court in Hunan Province, China, means the firm will pay…
You’ve reached your free article limit for this month. Subscribe for free to continue reading and unlock full access.
Already a subscriber? Login
